Georg Semmler; Lorenz Balcar; Mattias Mandorfer

doi:10.3350/cmh.2025.0149

Articles

Page Path

Reply to Correspondence

Decreasing systemic inflammation after TIPS: Still hope for the liver: Reply to correspondence on “Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis”

Georg Semmler^1,2,3,4

, Lorenz Balcar^1,2

, Mattias Mandorfer^1,2

Clinical and Molecular Hepatology 2025;31(2):e224-e225.
Published online: February 17, 2025

DOI: https://doi.org/10.3350/cmh.2025.0149

¹Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria

²Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria

³Centre for Liver Research, Department of Gastroenterology and Hepatology, Odense University Hospital, Odense, Denmark

⁴Institute of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark

Corresponding author : Georg Semmler Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria Tel: +43 1 40400 47440, Fax: +43 1 40400 47350, E-mail: georg.semmler@meduniwien.ac.at

Editor: Han Ah Lee, Chung-Ang University College of Medicine, Korea

• Received: February 8, 2025 • Accepted: February 14, 2025

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

6,284 Views
43 Download
1 Web of Science
1 Crossref
1 Scopus

Full Article

Download PDF

FOOTNOTES
Abbreviations
REFERENCES

See the article "TIPS insertion and systemic inflammation: Is it ever too late to lower portal pressure? Correspondence to editorial on “Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis”" on page e176.

Keywords: Cirrhosis; TIPS; Transjugular intrahepatic portosystemic shunt

Dear Editor,

We thank Anja Thiede and Benjamin Maasoumy [1] for adding additional important thoughts on the potential effect of transjugular intrahepatic portosystemic shunt (TIPS) on systemic inflammation (SI) [2,3], highlighting the anti-inflammatory potency of TIPS as being likely higher compared to other treatment options such as non-selective beta-blockers [4,5] a cornerstone for the therapy of clinically significant portal hypertension [6,7]. Just yesterday, the final results from the LIVERHOPE study were published, showing no effect of combined simvastatin 20 mg with rifaximin 1,200 mg on the incidence of acute-on-chronic liver failure or death in patients with decompensated cirrhosis (~80% with ChildPugh B, 90% with previous ascites, but only 37% with ascites grade 2 or 3 at study inclusion) [8]. While only data on Creactive protein (CRP) were shown, these indicated no effect on CRP over the study period or between the simvastatin/rifaximin or placebo groups, which is likely related to a less advanced patient population at study inclusion, as outlined above. Also, median CRP levels were within the normal range at baseline, making any anti-inflammatory effect of such a treatment less likely (compare regression to the mean), acknowledging all limitations of CRP as reflecting the full anti-inflammatory properties of simvastatin/rifaximin. Here, the promising data after TIPS showing a reduction in SI that indeed translated into an improved outcome [9] still give “hope” for a disease-modifying treatment in patients with (refractory) ascites that otherwise suffer from high mortality [10,11], and confirmatory data from randomized controlled trials are eagerly awaited.

FOOTNOTES

Authors’ contribution

Drafting of the manuscript (G.S., L.B., M.M.), critical revision of the manuscript for important intellectual content (G.S., L.B., M.M.).

Conflicts of Interest

G.S. received travel support from Amgen. L.B. has nothing to disclose. M.M. received grant support from Echosens, served as a consultant and/or advisory board member and/or speaker for AbbVie, Collective Acumen, Echosens, Gilead, Ipsen, Takeda, and W. L. Gore & Associates and received travel support from AbbVie and Gilead.

Abbreviations

CRP

C-reactive protein

systemic inflammation

TIPS

transjugular intrahepatic portosystemic shunt

REFERENCES

1. Tiede A, Maasoumy B. TIPS insertion and systemic inflammation: Is it ever too late to lower portal pressure: Correspondence to editorial on “Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis”. Clin Mol Hepatol 2025;31:e176-e179.
Article
PubMed
PMC
PDF
2. Tiede A, Stockhoff L, Liu Z, Rieland H, Mauz JB, Ohlendorf V, et al. Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis. Clin Mol Hepatol 2025;31:240-255.
PubMed
3. Semmler G, Balcar L, Mandorfer M. Treating systemic inflammation by transjugular intrahepatic portosystemic shunt: Editorial on “Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis”. Clin Mol Hepatol 2025;31:615-619.
Article
PubMed
PMC
PDF
4. Jachs M, Hartl L, Schaufler D, Desbalmes C, Simbrunner B, Eigenbauer E, et al. Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes. Gut 2021;70:1758-1767.
Article
PubMed
5. Reiberger T, Mandorfer M. Beta adrenergic blockade and decompensated cirrhosis. J Hepatol 2017;66:849-859.
Article
PubMed
6. Liu C, You H, Zeng QL, Wong YJ, Wang B, Grgurevic I, et al. Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306). Clin Mol Hepatol 2025;31:105-118.
PubMed
7. Brujats A, Villanueva C. Examining the therapeutic landscape of beta-blockers in portal hypertension. Clin Mol Hepatol 2024;30:1055-1059.
Article
PubMed
PMC
PDF
8. Pose E, Jiménez C, Zaccherini G, Campion D, Piano S, Uschner FE, et al. Simvastatin and rifaximin in decompensated cirrhosis: A randomized clinical trial. JAMA 2025;333:864-874.
PubMed
PMC
9. Kornfehl A, Tiede A, Hemetsberger P, Kappel J, Müllner-Bucsics T, Stockhoff L, et al. Decreasing interleukin-6 levels after TIPS predict outcomes in decompensated cirrhosis. JHEP Reports 2024;7:101308.
Article
PubMed
PMC
10. Balcar L, Tonon M, Semmler G, Calvino V, Hartl L, Incicco S, et al. Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event. JHEP Rep 2022;4:100513.
Article
PubMed
PMC
11. Tonon M, Balcar L, Semmler G, Calvino V, Scheiner B, Incicco S, et al. Etiological cure prevents further decompensation and mortality in patients with cirrhosis with ascites as the single first decompensating event. Hepatology 2023;78:1149-1158.
Article
PubMed

Figure & Data

References

Citations

Citations to this article as recorded by

Systemic inflammatory indexes as predictors of 18-month mortality among cirrhotic patients receiving transjugular intrahepatic portosystemic shunt
Jie Cheng, Xiaobing Wang, Lihua Zhou, Xiaojia Chen, Nuer Tang, Feng Zhou, Feng Ding, Yuan Yang, Jun Lin, Liping Chen
Annals of Medicine.2025;[Epub] CrossRef

Cite

CITE

export

Copy Download

Format
XML Download

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Decreasing systemic inflammation after TIPS: Still hope for the liver: Reply to correspondence on “Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis”

Clin Mol Hepatol. 2025;31(2):e224-e225. Published online February 17, 2025

DOI: https://doi.org/10.3350/cmh.2025.0149

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
bib — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Clin Mol Hepatol. 2025;31(2):e224-e225. Published online February 17, 2025

DOI: https://doi.org/10.3350/cmh.2025.0149

Articles

Page Path

Decreasing systemic inflammation after TIPS: Still hope for the liver: Reply to correspondence on “Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis”

Full Article

FOOTNOTES

Abbreviations

REFERENCES

Figure & Data

References

Citations

CITE

Download Citation

Format:

Include:

Related articles

ABOUT

BROWSE ARTICLES

FOR CONTRIBUTORS